Blue Fin Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$318K Sell
5,245
-1,611
-23% -$93.9K 0.05% 128
2025
Q4
$370K Sell
6,856
-283
-4% -$13.6K 0.06% 122
2025
Q3
$322K Sell
7,139
-74
-1% -$3.46K 0.05% 126
2025
Q2
$334K Hold
7,213
0.06% 122
2025
Q1
$440K Sell
7,213
-61
-0.8% -$3.56K 0.09% 102
2024
Q4
$411K Sell
7,274
-32
-0.4% -$1.79K 0.08% 105
2024
Q3
$378K Hold
7,306
0.07% 113
2024
Q2
$303K Hold
7,306
0.06% 124
2024
Q1
$396K Sell
7,306
-573
-7% -$29.2K 0.09% 109
2023
Q4
$404K Sell
7,879
-41
-0.5% -$2.15K 0.1% 101
2023
Q3
$460K Sell
7,920
-109
-1% -$6.68K 0.13% 93
2023
Q2
$513K Hold
8,029
0.15% 86
2023
Q1
$536K Sell
8,029
-249
-3% -$17.6K 0.17% 84
2022
Q4
$596K Sell
8,278
-26
-0.3% -$1.96K 0.22% 79
2022
Q3
$590K Hold
8,304
0.22% 78
2022
Q2
$639K Sell
8,304
-168
-2% -$12.8K 0.23% 74
2022
Q1
$618K Sell
8,472
-36
-0.4% -$2.42K 0.18% 80
2021
Q4
$530K Sell
8,508
-350
-4% -$20.5K 0.15% 87
2021
Q3
$524K Sell
8,858
-297
-3% -$19.6K 0.16% 80
2021
Q2
$611K Sell
9,155
-320
-3% -$20.9K 0.19% 76
2021
Q1
$598K Sell
9,475
-110
-1% -$6.84K 0.2% 74
2020
Q4
$594K Sell
9,585
-214
-2% -$13.2K 0.21% 74
2020
Q3
$590K Sell
9,799
-256
-3% -$15.4K 0.24% 73
2020
Q2
$591K Sell
10,055
-1,325
-12% -$79.3K 0.26% 72
2020
Q1
$634K Sell
11,380
-493
-4% -$30.1K 0.35% 71
2019
Q4
$762K Hold
11,873
0.36% 77
2019
Q3
$602K Sell
11,873
-1,197
-9% -$56.3K 0.32% 79
2019
Q2
$592K Sell
13,070
-225
-2% -$10.5K 0.31% 83
2019
Q1
$634K Sell
13,295
-84
-0.6% -$4.18K 0.33% 80
2018
Q4
$695K Sell
13,379
-1,331
-9% -$71.5K 0.42% 68
2018
Q3
$913K Sell
14,710
-1,475
-9% -$87.5K 0.45% 62
2018
Q2
$895K Sell
16,185
-1,340
-8% -$72.4K 0.48% 64
2018
Q1
$1.11M Buy
17,525
+380
+2% +$24.4K 0.63% 47
2017
Q4
$1.05M Sell
17,145
-230
-1% -$14.4K 0.61% 53
2017
Q3
$1.11M Sell
17,375
-150
-0.9% -$8.76K 0.68% 44
2017
Q2
$976K Sell
17,525
-1,105
-6% -$60.1K 0.63% 50
2017
Q1
$1.01M Sell
18,630
-25
-0.1% -$1.37K 0.62% 51
2016
Q4
$1.09M Buy
18,655
+2,270
+14% +$124K 0.72% 45
2016
Q3
$883K Buy
16,385
+250
+2% +$16.1K 0.72% 47
2016
Q2
$1.19M Sell
16,135
-325
-2% -$23K 0.98% 33
2016
Q1
$1.05M Sell
16,460
-885
-5% -$55.8K 0.89% 35
2015
Q4
$1.19M Sell
17,345
-180
-1% -$11.9K 0.92% 34
2015
Q3
$1.04M Sell
17,525
-370
-2% -$23.5K 0.81% 39
2015
Q2
$1.19M Hold
17,895
0.86% 32
2015
Q1
$1.15M Sell
17,895
-20
-0.1% -$1.25K 0.83% 37
2014
Q4
$1.06M Buy
17,915
+520
+3% +$29.3K 0.8% 45
2014
Q3
$890K Buy
17,395
+375
+2% +$18.7K 0.71% 48
2014
Q2
$826K Buy
17,020
+700
+4% +$34.5K 0.66% 54
2014
Q1
$848K Sell
16,320
-877
-5% -$46.7K 0.75% 45
2013
Q4
$914K Buy
+17,197
New +$876K 0.81% 40

Other funds holding BMY

Blue Fin Capital's BMY Position: Q1 2026 in Review

Blue Fin Capital reduced its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, selling an estimated $93.9K and leaving 5,245 shares worth $318K. The position accounts for 0.05% of the portfolio, ranked #128.

Blue Fin Capital first reported a position in BMY in Q4 2013 and has held it in 50 quarters since. The position peaked at $1.19M in Q4 2015. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Blue Fin Capital held 5,245 shares of Bristol-Myers Squibb worth $318K as of Q1 2026.
  • Blue Fin Capital sold 1,611 Bristol-Myers Squibb shares in Q1 2026, an estimated $93.9K.
  • Bristol-Myers Squibb made up 0.05% of Blue Fin Capital's portfolio in Q1 2026, its #128 holding.
  • Blue Fin Capital first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 50 quarters since.
  • Blue Fin Capital's Bristol-Myers Squibb position peaked at $1.19M in Q4 2015.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Blue Fin Capital's 13F filing for Q1 2026, filed 28 May 2026.